Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

Saye H KhooRichard FitzgeraldThomas FletcherSean EwingsThomas JakiRebecca LyonNichola DownsLauren WalkerOlana Tansley-HancockWilliam GreenhalfChristie WoodsHelen ReynoldsEllice MarwoodPavel MozgunovEmily AdamsKatie BullockWayne HolmanMarcin D BulaJennifer L GibneyGeoffrey SaundersAndrea CorkhillColin HaleKerensa ThorneJustin ChiongSusannah CondieHenry PertinezWendy PainterEmma WrixonLucy JohnsonSara YeatsKim MallardMike RadfordKeira FinesVictoria ShawAndrew OwenDavid G LallooMichael JacobsGareth Griffiths

Published in: The Journal of antimicrobial chemotherapy (2021)

Molnupiravir was safe and well tolerated; a dose of 800 mg twice daily for 5 days was recommended for Phase II evaluation.

Keyphrases

phase ii
open label
clinical trial
sars cov
phase iii
double blind
placebo controlled
phase ii study
study protocol
clinical evaluation